ATHA - Athira Pharma Inc

ATHA - Athira Pharma Inc

https://www.athira.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 - Athira Pharma ( NASDAQ:ATHA )

Benzinga • 1 month ago • score: 0.37

BOTHELL, Wash., Aug. 14, 2025 ( GLOBE NEWSWIRE ) -- Athira Pharma, Inc. ATHA, a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented results from its Phase 1 clinical trial of ATH-1105 in healthy volunteers ...

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit - Athira Pharma ( NASDAQ:ATHA )

Benzinga • 4 months ago • score: 0.26

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development On-track to enable initiation of a clinical trial in ALS patients in late 2025

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND - Athira Pharma ( NASDAQ:ATHA )

Benzinga • 9 months, 1 week ago • score: 0.18

BOTHELL, Wash., Dec. 06, 2024 ( GLOBE NEWSWIRE ) -- Athira Pharma, Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Athira Pharma, Inc., a late-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. The company is headquartered in Bothell, Washington.

52W High

$0.83

52W Low

$0.22

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

3.02

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

1.31

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

0.48

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

8.70%

Institutions (25–75% balanced)

45.04%

Shares Outstanding

39,439,300

Float

25,302,700

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-1.54

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-1.04%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0022

Previous

-0.0016

Trend

Falling

Signal Cross

No cross

As of

Sep. 11, 2025